avacincaptad pegol GA
Selected indexed studies
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. (Ophthalmology, 2021) [PMID:32882310]
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. (Ophthalmol Retina, 2024) [PMID:38719191]
- Treatment of dry age-related macular degeneration: A review. (Clin Exp Ophthalmol, 2023) [PMID:37737509]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treatment of dry age-related macular degeneration: A review. (2023) pubmed
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. (2021) pubmed
- C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. (2024) pubmed
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. (2024) pubmed
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. (2023) pubmed
- "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy". (2024) pubmed
- Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy. (2025) pubmed
- Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study. (2025) pubmed
- A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan. (2024) pubmed
- Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol. (2025) pubmed